NGeneBio Co. Ltd.
NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myelopro… Read more
NGeneBio Co. Ltd. (354200) - Net Assets
Latest net assets as of September 2025: ₩15.81 Billion KRW
Based on the latest financial reports, NGeneBio Co. Ltd. (354200) has net assets worth ₩15.81 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩43.94 Billion) and total liabilities (₩28.13 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩15.81 Billion |
| % of Total Assets | 35.99% |
| Annual Growth Rate | N/A |
| 5-Year Change | -59.04% |
| 10-Year Change | N/A |
| Growth Volatility | 430.44 |
NGeneBio Co. Ltd. - Net Assets Trend (2018–2024)
This chart illustrates how NGeneBio Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NGeneBio Co. Ltd. (2018–2024)
The table below shows the annual net assets of NGeneBio Co. Ltd. from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩16.98 Billion | +4.58% |
| 2023-12-31 | ₩16.23 Billion | -35.83% |
| 2022-12-31 | ₩25.30 Billion | -25.59% |
| 2021-12-31 | ₩34.00 Billion | -17.98% |
| 2020-12-31 | ₩41.45 Billion | +1056.88% |
| 2019-12-31 | ₩3.58 Billion | +229.20% |
| 2018-12-31 | ₩-2.77 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to NGeneBio Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5877545294000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩19.82 Billion | 116.74% |
| Other Components | ₩63.73 Billion | 375.37% |
| Total Equity | ₩16.98 Billion | 100.00% |
NGeneBio Co. Ltd. Competitors by Market Cap
The table below lists competitors of NGeneBio Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Korea SPAC 2
KQ:206400
|
$24.17 Million |
|
Aztek Teknoloji Urunleri Ticaret A.S.
IS:AZTEK
|
$24.19 Million |
|
Panache Digilife Limited
NSE:PANACHE
|
$24.19 Million |
|
Link Net Tbk
JK:LINK
|
$24.19 Million |
|
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
|
$24.17 Million |
|
Youngbo Chem
KO:014440
|
$24.16 Million |
|
Future Fuels Inc.
V:FTUR
|
$24.15 Million |
|
Nava Nakorn Public Company Limited
BK:NNCL
|
$24.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NGeneBio Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 16,294,798,080 to 16,977,180,790, a change of 682,382,710 (4.2%).
- Net loss of 12,627,629,430 reduced equity.
- New share issuances of 12,592,565,930 increased equity.
- Other factors increased equity by 717,446,210.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-12.63 Billion | -74.38% |
| Share Issuances | ₩12.59 Billion | +74.17% |
| Other Changes | ₩717.45 Million | +4.23% |
| Total Change | ₩- | 4.19% |
Book Value vs Market Value Analysis
This analysis compares NGeneBio Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.69x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | ₩-227.02 | ₩2040.00 | x |
| 2019-12-31 | ₩293.30 | ₩2040.00 | x |
| 2020-12-31 | ₩3393.14 | ₩2040.00 | x |
| 2021-12-31 | ₩2734.94 | ₩2040.00 | x |
| 2022-12-31 | ₩2019.58 | ₩2040.00 | x |
| 2023-12-31 | ₩1264.22 | ₩2040.00 | x |
| 2024-12-31 | ₩758.92 | ₩2040.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NGeneBio Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -74.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -221.89%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.94x
- Recent ROE (-74.38%) is below the historical average (-61.10%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -173.78% | 0.13x | 0.00x | ₩-2.14 Billion |
| 2019 | -191.60% | -464.61% | 0.11x | 3.75x | ₩-7.22 Billion |
| 2020 | -19.85% | -331.86% | 0.05x | 1.19x | ₩-12.37 Billion |
| 2021 | -24.80% | -117.70% | 0.16x | 1.29x | ₩-11.83 Billion |
| 2022 | -38.68% | -88.82% | 0.20x | 2.22x | ₩-12.32 Billion |
| 2023 | -78.36% | -293.48% | 0.10x | 2.59x | ₩-14.40 Billion |
| 2024 | -74.38% | -221.89% | 0.17x | 1.94x | ₩-14.33 Billion |
Industry Comparison
This section compares NGeneBio Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $259,224,420,269
- Average return on equity (ROE) among peers: -0.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NGeneBio Co. Ltd. (354200) | ₩15.81 Billion | 0.00% | 1.78x | $24.17 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.37 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $229.70 Million |
| Green Cross Holdings Preference Shares (005257) | $1.88 Trillion | -2.88% | 0.99x | $409.02 Million |
| Pharmicell (005690) | $76.66 Billion | 10.78% | 0.43x | $453.92 Million |
| GeneOne Life Science Inc (011000) | $23.71 Billion | -35.27% | 0.34x | $52.94 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $19.73 Billion | 2.26% | 0.29x | $14.76 Million |
| Seoulin Bioscience Co.Ltd (038070) | $59.92 Billion | 8.17% | 0.31x | $27.84 Million |
| Hyundai Bioscience Co. Ltd (048410) | $60.94 Billion | 0.00% | 2.69x | $964.67 Million |
| iNtRON Biotechnology Inc (048530) | $49.15 Billion | -1.24% | 0.21x | $83.99 Million |
| Synergy Innovation Co. Ltd (048870) | $71.09 Billion | 0.00% | 0.77x | $77.78 Million |